PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.36%
Revenue growth similar to MRVL's 9.90%. Walter Schloss would see if both companies share industry tailwinds.
17.05%
Gross profit growth above 1.5x MRVL's 5.53%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
41.52%
EBIT growth above 1.5x MRVL's 21.21%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
42.32%
Operating income growth above 1.5x MRVL's 21.21%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
40.25%
Net income growth above 1.5x MRVL's 16.19%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
43.18%
EPS growth above 1.5x MRVL's 18.18%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
40.91%
Diluted EPS growth above 1.5x MRVL's 9.09%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.93%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.91%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
0.31%
Dividend growth above 1.5x MRVL's 0.04%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
67.75%
OCF growth above 1.5x MRVL's 3.15%. David Dodd would confirm a clear edge in underlying cash generation.
80.52%
FCF growth above 1.5x MRVL's 13.55%. David Dodd would verify if the firm’s strategic investments yield superior returns.
67.30%
10Y revenue/share CAGR under 50% of MRVL's 318.80%. Michael Burry would suspect a lasting competitive disadvantage.
58.50%
5Y revenue/share CAGR above 1.5x MRVL's 17.60%. David Dodd would look for consistent product or market expansions fueling outperformance.
2.76%
3Y revenue/share CAGR under 50% of MRVL's 18.03%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
152.27%
10Y OCF/share CAGR 1.25-1.5x MRVL's 127.66%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
64.60%
Positive OCF/share growth while MRVL is negative. John Neff might see a comparative advantage in operational cash viability.
32.57%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
155.09%
Below 50% of MRVL's 556.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
210.77%
5Y net income/share CAGR above 1.5x MRVL's 6.36%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
9.70%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
38.59%
Below 50% of MRVL's 116.59%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
34.39%
5Y equity/share CAGR at 75-90% of MRVL's 45.49%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
3.61%
Below 50% of MRVL's 15.57%. Michael Burry suspects a serious short-term disadvantage in building book value.
1337.84%
Dividend/share CAGR of 1337.84% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
174.90%
Dividend/share CAGR of 174.90% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
132.42%
3Y dividend/share CAGR of 132.42% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
12.69%
AR growth well above MRVL's 16.34%. Michael Burry fears inflated revenue or higher default risk in the near future.
1.75%
Inventory shrinking or stable vs. MRVL's 23.89%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-5.94%
Negative asset growth while MRVL invests at 1.62%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.53%
We have a declining book value while MRVL shows 2.53%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-17.76%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.64%
Our R&D shrinks while MRVL invests at 4.87%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.46%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.